Administration of Nanocurcumin in Mice Models of Endometriosis as an Effort to Improve Folliculogenesis

The purpose of this study is to ascertain how nanocurcumin 0-50 nm affects malondialdehyde (MDA) levels, folliculogenesis, and the quantity of corpus luteum (CL) in a mice model of endometriosis. 24 mice were used in this scientific experiment, and they were split up into 4 treatment groups; positive control (C+) as mice model of endometriosis, Treatment 1 (T1) as mice model of endometriosis given nanocurcumin 0-50 nm (2.5 mg/KgBW) PO, Treatment 2 (T2) mice given nanocurcumin (5 mg/KgBW) and Treatment 3 (T3) as mice model of endometriosis treated with nanocurcumin (10 mg/KgBW). The nanocurcumin was administered for 14 days. The findings demonstrated that, out of all treatment groups, T3 had the lowest MDA level (20.78±4.58 ng/ml) and statistically significant (p<0.05) compared to C+, T1 and T2. Significant differences (p<0.05) were observed in the number of primary, secondary, and tertiary follicles at T3, from C+, T1, and T2, according to the folliculogenesis profile. Although the number of Graafian follicles tended to grow, there was no discernible difference between the number of Graafian follicles and the CL. It can be concluded that the administration of nanocurcumin for 14 days decreased MDA levels and increased the folliculogenesis profile. Administration of nanocurcumin at a dose of 10 mg/KgBW caused a decrease in MDA levels and an improvement in the folliculogenesis profile. Thus, administering nanocurcumin could improve the quality of folliculogenesis in endometriosis sufferers and improve reproductive health.